The US&nbspSupreme Court sided with the Trump administration and against China on Thursday on a disputed aspect of their fraught trade relationship, throwing out a lower court ruling that had allowed two Chinese vitamin C makers to escape $148 million in damages for violating American antitrust law.

In a case that brought the trade conflict between the world's two largest economies before the top US&nbspcourt, the justices ruled 9-0 that the lower court gave too much deference to Chinese government filings in the case explaining China's regulatory policy.

The justices sent the case back for reconsideration by the New York-based 2nd US&nbspCircuit Court of Appeals, which in 2016 threw out the damages won by two American vitamin C buyers.

Writing for the court, Justice Ruth Bader Ginsburg wrote that while US&nbspcourts should give "respectful consideration" to a foreign government's interpretation of its own law, they are not "bound to accord conclusive effect to the foreign government's statements."

Lawyers for the US&nbspand Chinese governments faced off in April before the justices. The Supreme Court took the unusual step of letting China present arguments even though it is not an official party in the case, a privilege typically reserved for the US&nbspJustice Department.

The price-fixing case dates back to 2005 when Texas-based Animal Science Products Inc and New Jersey-based The Ranis Co Inc accused Hebei Welcome Pharmaceutical and North China Pharmaceutical Group and other Chinese vitamin C makers of antitrust violations.

China intervened in the case, asking the trial court to dismiss the allegations in part because its laws had forced Chinese companies to comply with government-mandated pricing regimes.

A US&nbspfederal judge questioned the credibility of the Chinese submissions and, after a 2013 jury trial, awarded the two American companies $147.8 million in damages.

The New York-based 2nd U.S. Circuit Court of Appeals overturned the judgment in 2016, saying that when a foreign government directly participates in a case American courts are obligated to defer to that country's characterization of its own laws.

The Supreme Court itself did not weigh in on the correct interpretation of Chinese law, but Ginsburg said questions remained over "whether Chinese law required the Chinese sellers' conduct."

China and the United States are locked in a simmering trade dispute. President Donald Trump has accused China of unfair trade practices and threatened to impose tariffs on up to $150 billion in Chinese goods over allegations of intellectual property theft. China has warned of retaliation.

In a case that brought the trade conflict between the world's two largest economies before the top US court, the justices ruled 9-0 that the lower court gave too much deference to Chinese government filings in the case explaining China's regulatory policy.

The US&nbspSupreme Court sided with the Trump administration and against China on Thursday on a disputed aspect of their fraught trade relationship, throwing out a lower court ruling that had allowed two Chinese vitamin C makers to escape $148 million in damages for violating American antitrust law. In a case that brought the trade conflict between the world's two largest economies before the top US&nbspcourt, the justices ruled 9-0 that the lower court gave too much deference to Chinese government filings in the case explaining China's regulatory policy. The justices sent the case back for reconsideration by the New York-based 2nd US&nbspCircuit Court of Appeals, which in 2016 threw out the damages won by two American vitamin C buyers. Writing for the court, Justice Ruth Bader Ginsburg wrote that while US&nbspcourts should give "respectful consideration" to a foreign government's interpretation of its own law, they are not "bound to accord conclusive effect to the foreign government's statements." Lawyers for the US&nbspand Chinese governments faced off in April before the justices. The Supreme Court took the unusual step of letting China present arguments even though it is not an official party in the case, a privilege typically reserved for the US&nbspJustice Department. The price-fixing case dates back to 2005 when Texas-based Animal Science Products Inc and New Jersey-based The Ranis Co Inc accused Hebei Welcome Pharmaceutical and North China Pharmaceutical Group and other Chinese vitamin C makers of antitrust violations. China intervened in the case, asking the trial court to dismiss the allegations in part because its laws had forced Chinese companies to comply with government-mandated pricing regimes. A US&nbspfederal judge questioned the credibility of the Chinese submissions and, after a 2013 jury trial, awarded the two American companies $147.8 million in damages. The New York-based 2nd U.S. Circuit Court of Appeals overturned the judgment in 2016, saying that when a foreign government directly participates in a case American courts are obligated to defer to that country's characterization of its own laws. The Supreme Court itself did not weigh in on the correct interpretation of Chinese law, but Ginsburg said questions remained over "whether Chinese law required the Chinese sellers' conduct." China and the United States are locked in a simmering trade dispute. President Donald Trump has accused China of unfair trade practices and threatened to impose tariffs on up to $150 billion in Chinese goods over allegations of intellectual property theft. China has warned of retaliation.

US Supreme Court hands Trump win in China antitrust case

chinese-vitamin-c

Chinese Vitamin C, News on Chinese Vitamin C, stories on Chinese Vitamin C, articles on Chinese Vitamin C, Chinese Vitamin C stories at Wion, Chinese Vitamin C news, Chinese Vitamin C latest news

chinese vitamin-c

US Supreme Court hands Trump win in China antitrust case